AstraZeneca earmarks $1.5B for end-to-end ADC factory in Singapore

As­traZeneca said on Mon­day morn­ing it is build­ing a new an­ti­body-drug con­ju­gate fa­cil­i­ty in Sin­ga­pore worth $1.5 bil­lion.

The UK phar­ma said this will be its first fa­cil­i­ty that will make every step of the ADC man­u­fac­tur­ing process at a com­mer­cial scale. Con­struc­tion will be­gin by the end of the year and is es­ti­mat­ed to be op­er­a­tional in 2029.

“Sin­ga­pore is one of the world’s most at­trac­tive coun­tries for in­vest­ment giv­en its rep­u­ta­tion for ex­cel­lence in com­plex man­u­fac­tur­ing,” CEO Pas­cal So­ri­ot said in a press re­lease. The fa­cil­i­ty would be de­signed to house the pro­duc­tion of an­ti­bod­ies, chemother­a­py and a link­er that would meld these two com­po­nents to­geth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.